Vertex Initiates FDA Rolling Review for Non-Opioid Pain Medication Suzetrigine (VX-548)

1. Vertex Pharmaceuticals has begun the process of a rolling submission for suzetrigine (VX-548), a non-opioid pain medication, with the U.S. Food and Drug Administration (FDA).
2. The submission will include two 12-week trials evaluating the once-daily suzetrigine against a placebo, focusing on changes to the weekly average of pain.
3. Vertex aims to complete the submission in the second quarter of 2024.
4. Suzetrigine has previously met its main goal in late-stage trials.
5. The drug is being developed to address acute pain management without the use of opioids.